CDK1 and breast cancer: In BC, VIRMA directly interacted with CDK1 transcripts and prolonged their half-life, but VIRMA knockdown did not change m6A-modified CDK1 mRNA level, indicating VIRMA regulates CDK1 mRNA stability in an m6A-independent manner [83].